Nectar Biopharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 30-07-2024
- Paid Up Capital ₹ 1.00 Cr
as on 30-07-2024
- Company Age 9 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.45 M
as on 30-07-2024
- Satisfied Charges ₹ 22.50 Cr
as on 30-07-2024
- Revenue -38.99%
(FY 2023)
- Profit 8.55%
(FY 2023)
- Ebitda 52.23%
(FY 2023)
- Net Worth 7.54%
(FY 2023)
- Total Assets 41.42%
(FY 2023)
About Nectar Biopharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹1.45 M. The company has closed loans amounting to ₹22.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Aryan Goyal, Saurabh Goyal, and Rajinder Sharma serve as directors at the Company.
- CIN/LLPIN
U24100MH2015PTC314118
- Company No.
314118
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Apr 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Nectar Biopharma Private Limited offer?
Nectar Biopharma Private Limited offers a wide range of products and services, including Women Care, Feminine Hygiene, Sexual Wellness, Condoms.
Who are the key members and board of directors at Nectar Biopharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aryan Goyal  | Director | 27-Sep-2021 | Current |
| Saurabh Goyal | Director | 14-Mar-2018 | Current |
| Rajinder Sharma | Director | 25-Jul-2022 | Current |
Financial Performance and Corporate Structure Insights of Nectar Biopharma.
Nectar Biopharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 38.99% decrease. The company also saw a slight improvement in profitability, with a 8.55% increase in profit. The company's net worth moved up by a moderate rise of 7.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nectar Biopharma?
In 2023, Nectar Biopharma had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nureca Healthcare Private LimitedActive 4 years 4 monthsAryan Goyal, Saurabh Goyal and 1 more are mutual person
Nureca Technologies Private LimitedActive 4 years 5 monthsAryan Goyal, Saurabh Goyal and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 04 Dec 2019 | ₹1.45 M | Open |
Others Creation Date: 26 Feb 2019 | ₹22.50 Cr | Satisfied |
How Many Employees Work at Nectar Biopharma?
Nectar Biopharma has a workforce of 2 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nectar Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nectar Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
